vs
Side-by-side financial comparison of DELUXE CORP (DLX) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $535.2M, roughly 1.3× DELUXE CORP). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 2.2%, a 16.8% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 2.8%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 0.0%).
Deluxe Corporation is an American company that provides payment processing, data services, checks and promotional products, and merchant services. It operates in four divisions: B2B payments, data, print, and merchant services. As of 2025, the company serves millions of small businesses and thousands of financial institutions, processing more than $2.8 trillion in payments annually. While its legacy business centers on check printing and other printed products, payments and data services now ...
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
DLX vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $535.2M | $708.5M |
| Net Profit | $12.0M | $135.1M |
| Gross Margin | 52.2% | — |
| Operating Margin | 8.9% | 21.6% |
| Net Margin | 2.2% | 19.1% |
| Revenue YoY | 2.8% | 32.0% |
| Net Profit YoY | -5.0% | 15.5% |
| EPS (diluted) | $0.25 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $535.2M | $708.5M | ||
| Q3 25 | $540.2M | $659.9M | ||
| Q2 25 | $521.3M | $603.3M | ||
| Q1 25 | $536.5M | $558.6M | ||
| Q4 24 | $520.6M | $536.6M | ||
| Q3 24 | $528.4M | $533.3M | ||
| Q2 24 | $537.8M | $528.1M | ||
| Q1 24 | $535.0M | $511.0M |
| Q4 25 | $12.0M | $135.1M | ||
| Q3 25 | $33.7M | $111.1M | ||
| Q2 25 | $22.4M | $90.3M | ||
| Q1 25 | $14.0M | $114.6M | ||
| Q4 24 | $12.6M | $117.0M | ||
| Q3 24 | $8.9M | $96.4M | ||
| Q2 24 | $20.5M | $88.4M | ||
| Q1 24 | $10.8M | $102.6M |
| Q4 25 | 52.2% | — | ||
| Q3 25 | 53.9% | — | ||
| Q2 25 | 53.6% | — | ||
| Q1 25 | 52.4% | — | ||
| Q4 24 | 52.3% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 53.7% | — | ||
| Q1 24 | 53.0% | — |
| Q4 25 | 8.9% | 21.6% | ||
| Q3 25 | 14.0% | 21.5% | ||
| Q2 25 | 11.7% | 20.9% | ||
| Q1 25 | 9.0% | 20.3% | ||
| Q4 24 | 9.0% | 23.4% | ||
| Q3 24 | 7.9% | 21.1% | ||
| Q2 24 | 11.0% | 19.9% | ||
| Q1 24 | 8.3% | 20.4% |
| Q4 25 | 2.2% | 19.1% | ||
| Q3 25 | 6.2% | 16.8% | ||
| Q2 25 | 4.3% | 15.0% | ||
| Q1 25 | 2.6% | 20.5% | ||
| Q4 24 | 2.4% | 21.8% | ||
| Q3 24 | 1.7% | 18.1% | ||
| Q2 24 | 3.8% | 16.7% | ||
| Q1 24 | 2.0% | 20.1% |
| Q4 25 | $0.25 | $4.65 | ||
| Q3 25 | $0.74 | $3.86 | ||
| Q2 25 | $0.50 | $3.10 | ||
| Q1 25 | $0.31 | $3.67 | ||
| Q4 24 | $0.28 | $3.67 | ||
| Q3 24 | $0.20 | $3.01 | ||
| Q2 24 | $0.46 | $2.75 | ||
| Q1 24 | $0.24 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.9M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $680.7M | $459.1M |
| Total Assets | $2.9B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.9M | $497.0M | ||
| Q3 25 | $25.8M | $285.4M | ||
| Q2 25 | $26.0M | $46.3M | ||
| Q1 25 | $30.3M | $441.4M | ||
| Q4 24 | $34.4M | $669.4M | ||
| Q3 24 | $41.3M | $656.9M | ||
| Q2 24 | $23.1M | $510.9M | ||
| Q1 24 | $23.5M | $407.0M |
| Q4 25 | $680.7M | $459.1M | ||
| Q3 25 | $664.1M | $293.6M | ||
| Q2 25 | $638.7M | $172.4M | ||
| Q1 25 | $622.5M | $593.6M | ||
| Q4 24 | $620.9M | $825.5M | ||
| Q3 24 | $612.7M | $881.4M | ||
| Q2 24 | $620.5M | $763.6M | ||
| Q1 24 | $608.4M | $671.5M |
| Q4 25 | $2.9B | $2.0B | ||
| Q3 25 | $2.6B | $1.8B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.6B | $1.9B | ||
| Q4 24 | $2.8B | $2.1B | ||
| Q3 24 | $2.6B | $2.1B | ||
| Q2 24 | $2.7B | $1.9B | ||
| Q1 24 | $2.7B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $102.1M | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | 8.53× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $102.1M | $192.7M | ||
| Q3 25 | $67.1M | $246.2M | ||
| Q2 25 | $51.1M | $148.5M | ||
| Q1 25 | $50.3M | $125.8M | ||
| Q4 24 | $60.2M | $190.7M | ||
| Q3 24 | $67.9M | $149.1M | ||
| Q2 24 | $39.6M | $116.4M | ||
| Q1 24 | $26.6M | $152.7M |
| Q4 25 | — | $188.1M | ||
| Q3 25 | — | $235.5M | ||
| Q2 25 | $27.8M | $142.4M | ||
| Q1 25 | $24.3M | $115.8M | ||
| Q4 24 | — | $183.0M | ||
| Q3 24 | $46.7M | $138.5M | ||
| Q2 24 | $11.4M | $103.5M | ||
| Q1 24 | $6.1M | $147.2M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 35.7% | ||
| Q2 25 | 5.3% | 23.6% | ||
| Q1 25 | 4.5% | 20.7% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | 8.8% | 26.0% | ||
| Q2 24 | 2.1% | 19.6% | ||
| Q1 24 | 1.1% | 28.8% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | 4.5% | 1.0% | ||
| Q1 25 | 4.8% | 1.8% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | 4.0% | 2.0% | ||
| Q2 24 | 5.2% | 2.4% | ||
| Q1 24 | 3.8% | 1.1% |
| Q4 25 | 8.53× | 1.43× | ||
| Q3 25 | 1.99× | 2.22× | ||
| Q2 25 | 2.28× | 1.65× | ||
| Q1 25 | 3.59× | 1.10× | ||
| Q4 24 | 4.77× | 1.63× | ||
| Q3 24 | 7.60× | 1.55× | ||
| Q2 24 | 1.94× | 1.32× | ||
| Q1 24 | 2.46× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLX
| Services | $247.9M | 46% |
| B2B Payments | $76.3M | 14% |
| Datadrivenmarketingsolutions | $68.5M | 13% |
| Promotional Solutions Revenue | $60.9M | 11% |
| Treasurymanagementsolutions | $59.8M | 11% |
| Other | $17.3M | 3% |
| Other Web Based Solutions | $4.6M | 1% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
